Interestingly, in several prospective epidemiologic studies, baseline FGF-23 levels did not predict future AMI [12,26] and in our previous study, patients with AMI without CS are characterized by FGF-23 levels comparable to those of stable CAD patients [9]. This evidence concerns the gene FGF23 and Cowden syndrome 1.